pityriasis rosea: a skin rash. It is benign but may inflict substantial discomfort in certain cases.Classically, it begins with a single "herald patch" lesion, followed in 1 or 2 weeks by a generalized body rash lasting up to 12 weeks, however usually around 6 - 8.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
342 |
4. Check minimum number of eventsNone |
342 |
5. Include endpointsNone |
342 |
6. Filter based on genotype QC (FinnGen only) |
307 |
Control definitions (FinnGen only)
- Control exclude
- L12_PAPULOSQUAMOUS
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- L40-L45
- Name in latin
- Pityriasis rosea
Similar endpoints
↥List of similar endpoints to
Pityriasis rosea
based on the number of shared cases.
Similar with more cases:
- Parapsoriasis
- Papulosquamous disorders
- Diseases of the skin and subcutaneous tissue
- Any prescribed medicine buy
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 2464 | 1398 | 1053 |
| Only index persons | 2221 | 1287 | 934 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.04 | 0.04 | 0.03 |
| Only index persons | 0.04 | 0.05 | 0.04 |
| Median age at first event (years) | |||
| Whole population | 25.89 | 28.71 | 22.08 |
| Only index persons | 25.96 | 28.92 | 21.89 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 307 | 221 | 86 |
| Unadjusted period prevalence (%) | 0.07 | 0.08 | 0.04 |
| Median age at first event (years) | 33.12 | 31.72 | 36.70 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 323
- Matched controls
- 3230
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L42
ICD-10 Finland
Pityriasis rosea
3596.1
307.7
284
6
69630
ICD-8 Finland
Psoriasis and similar disorders, Pityriasis rosea
+∞
32.9
31
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
6.9
30.4
51
85
L30.9
ICD-10 Finland
Dermatitis, unspecified
3.0
17.8
104
439
D07AC01
ATC
betamethasone; topical
2.7
16.4
142
731
R21
ICD-10 Finland
Rash and other nonspecific skin eruption
4.5
12.6
32
77
E0000UV, ,
ATC
2.2
11.1
160
991
D07AB08
ATC
desonide; topical
3.0
10.8
54
205
D07BB04
ATC
hydrocortisone butyrate and antiseptics; topical
2.7
9.9
59
245
Z01.5
ICD-10 Finland
Diagnostic skin and sensitization tests
2.8
8.9
48
189
6963A
ICD-9 Finland
Psoriasis and similar disorders, Pityriasis rosea
+∞
8.4
8
*
H02AB06
ATC
prednisolone; systemic
2.0
8.4
152
997
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
3.0
7.9
37
135
L04AD01
ATC
ciclosporin; systemic
12.4
7.1
12
10
L43.8
ICD-10 Finland
Other lichen planus
40.9
6.8
8
*
L40.0
ICD-10 Finland
Psoriasis vulgaris
12.6
6.6
11
9
D07XC01
ATC
betamethasone; topical
2.7
6.4
35
139
D07AB02
ATC
hydrocortisone butyrate; topical
1.9
6.1
101
630
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
42
215
2.10
4.36
1.5
1.2
89.45
301.40
u/ml
0.95
37
196
199
1605
1.62
4.25
10.4
8.8
4.19
3.98
e9/l
0.57
180
1400
60
362
1.81
3.86
2.3
2.1
—
—
—
0
0
171
1358
1.55
3.69
5.0
6.1
10.15
10.48
umol/l
0.22
162
1293
9
17
5.41
3.53
1.4
2.5
—
—
—
0
0
114
836
1.56
3.46
2.2
2.5
52.64
61.57
u/l
0.91
107
780
58
360
1.74
3.38
2.0
1.9
—
—
—
0
0
289
2647
1.87
3.06
6.1
5.4
1.70
1.78
mu/l
0.60
276
2497
45
268
1.79
3.02
1.6
1.7
—
—
—
0
0
25
121
2.16
3.02
1.6
1.4
—
—
—
0
0
231
2006
1.53
2.98
7.6
7.2
78.84
74.50
u/l
0.76
225
1892
112
844
1.50
2.92
1.4
1.4
0.93
1.75
u/ml
0.91
36
225
43
258
1.77
2.82
1.7
1.8
—
—
—
0
0
182
1517
1.46
2.80
5.9
5.0
6.35
6.43
mmol/l
0.23
169
1386
10
29
3.52
2.71
1.2
1.5
—
—
—
0
0
234
2061
1.49
2.62
5.6
3.9
10.20
9.38
mm/h
0.49
223
1923
39
233
1.77
2.60
3.3
4.3
0.93
1.41
mmol/l
0.28
34
196
5
7
7.23
2.55
1.6
2.6
197.00
149.86
%
—
5
7
64
443
1.55
2.43
2.4
2.1
—
—
—
0
0
246
2201
1.49
2.43
3.9
3.7
—
—
—
0
0
298
2792
1.87
2.39
16.5
12.6
19.69
20.64
mg/l
0.19
248
2229
65
454
1.54
2.38
3.7
3.3
174.42
276.75
ng/l
0.30
40
292
30
172
1.82
2.30
1.2
1.6
—
—
—
0
0
145
1189
1.40
2.29
7.4
7.1
1.22
1.21
mmol/l
0.41
129
1026
11
41
2.74
2.23
1.5
1.9
—
—
—
0
0
21
109
1.99
2.16
1.4
1.3
—
—
—
0
0
12
49
2.50
2.13
1.8
1.5
—
—
—
0
0
14
62
2.32
2.11
2.9
2.5
—
—
—
0
0
13
56
2.38
2.07
1.1
1.1
0.93
2.06
eliau/ml
—
6
29
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
6
15
4.05
2.05
1.7
1.7
197.17
124.40
%
—
6
15
93
720
1.41
2.01
4.0
2.8
0.20
0.32
e6/l
0.39
75
500
53
368
1.53
1.99
2.0
2.2
2.54
2.38
g/l
1.36
53
345
84
640
1.42
1.98
2.1
1.8
1.67
1.17
mg/l
0.29
66
482
227
2037
1.38
1.92
2.9
3.2
38.61
38.61
u/l
0.00
217
1955
107
857
1.37
1.88
3.5
3.2
38.92
37.65
ng/l
0.03
67
489
20
108
1.91
1.86
1.6
1.5
—
—
—
0
0
49
340
1.52
1.85
1.6
1.6
1170.00
1239.00
nmol/l
0.26
38
261
5
12
4.21
1.83
2.0
1.6
—
—
—
0
0
47
329
1.50
1.71
2.5
2.3
29.56
29.20
s
0.13
47
323
177
1546
1.32
1.69
4.8
3.5
0.03
0.00
estimate
0.49
35
287
6
19
3.20
1.67
2.7
1.6
—
—
—
0
0
139
1176
1.32
1.66
4.3
3.3
0.16
0.01
estimate
0.60
31
261
18
98
1.89
1.65
4.1
3.3
24.36
24.40
mmol/l
0.03
18
92
176
1541
1.31
1.63
4.7
3.5
0.00
0.00
estimate
-0.00
39
304
20
115
1.79
1.56
1.5
1.7
14.28
8.82
u/ml
—
6
30
5
15
3.37
1.53
2.2
3.7
319.00
579.27
u/ml
—
5
15
11
51
2.20
1.52
1.7
1.6
—
—
—
0
0
272
2552
1.42
1.48
4.3
4.3
5.65
5.73
mmol/l
0.48
261
2392
127
1075
1.30
1.47
6.9
6.4
1.21
1.21
mmol/l
0.01
118
991
7
28
2.53
1.46
1.4
2.9
106.00
106.46
mmol/l
—
7
28
172
1520
1.28
1.41
4.7
3.5
0.00
0.00
estimate
-0.00
38
307
20
119
1.73
1.41
4.2
3.2
1.02
1.02
ratio
0.54
20
112
98
807
1.31
1.38
4.4
3.6
0.00
0.00
estimate
-0.00
36
291
6
23
2.64
1.37
1.2
1.1
—
—
—
0
0
54
407
1.39
1.36
3.3
2.8
5.54
2.89
e6/l
0.51
36
186
144
1252
1.27
1.32
2.8
2.5
73.84
75.10
nmol/l
0.25
136
1156
16
91
1.80
1.31
1.3
1.1
—
—
—
0
0
9
43
2.12
1.31
1.8
1.4
—
—
—
0
0
274
2588
1.39
1.30
14.3
11.5
91.39
90.28
ml/min/173m2
0.39
245
2337
33
228
1.50
1.30
10.0
10.6
0.68
0.89
mmol/l
0.09
28
188
12
62
1.97
1.29
2.4
1.9
—
—
—
0
0
5
18
2.80
1.29
2.0
1.4
—
—
—
0
0
302
2906
1.60
1.28
12.4
10.1
26.34
25.90
u/l
0.20
297
2844
41
297
1.44
1.28
9.9
6.8
104.63
104.88
mmol/l
0.09
41
297
115
976
1.28
1.28
3.3
3.1
26.27
30.03
u/l
1.52
108
933
247
2300
1.31
1.28
5.0
4.5
14.50
14.49
pmol/l
0.01
234
2144
9
44
2.07
1.28
1.0
1.8
—
—
—
0
0
281
2670
1.40
1.24
4.3
4.4
1.49
1.49
mmol/l
0.01
270
2537
74
595
1.32
1.23
1.5
1.3
13.50
26.54
iu/ml
2.03
25
176
14
78
1.83
1.23
1.6
1.3
—
—
—
0
0
8
37
2.19
1.22
1.9
1.7
—
—
—
0
0
6
26
2.33
1.19
1.3
1.2
0.00
1.26
promille
—
6
20
84
691
1.29
1.19
4.4
4.0
11.10
9.90
mg/mmol
0.07
60
430
8
39
2.08
1.16
1.1
1.1
—
—
—
0
0
13
73
1.81
1.12
1.6
1.7
—
—
—
0
0
7
31
2.29
1.11
1.9
1.5
—
—
—
0
0
5
21
2.40
1.09
1.0
4.5
95.80
103.90
%
—
5
21
10
52
1.95
1.07
1.0
1.1
—
—
—
0
0
280
2675
1.35
1.04
4.5
4.4
4.76
4.70
mmol/l
0.49
270
2554
105
901
1.25
1.04
3.5
2.9
0.09
0.01
estimate
0.43
33
246
7
34
2.08
1.03
1.9
1.3
—
—
—
0
0
15
91
1.68
1.02
1.3
1.1
—
—
—
0
0
0
29
0.00
0.98
0.0
1.4
—
—
—
0
0
12
69
1.77
0.98
1.7
1.6
—
—
—
0
0
20
133
1.54
0.97
2.7
3.1
0.40
1.13
mmol/l
0.34
11
87
83
699
1.25
0.97
4.4
3.3
1.02
1.02
kg/l
0.20
53
445
13
77
1.72
0.96
2.5
1.7
—
—
—
0
0
281
2695
1.33
0.94
4.9
4.9
2.87
2.79
mmol/l
0.87
271
2561
6
28
2.16
0.92
1.5
2.9
1.19
1.19
mmol/l
—
6
28
119
1048
1.21
0.91
2.3
1.9
100.30
98.16
pmol/l
0.26
68
533
11
63
1.77
0.91
1.8
1.5
—
—
—
0
0
13
79
1.67
0.89
2.5
1.9
—
—
—
0
0
12
72
1.69
0.86
1.2
1.3
—
—
—
0
0
54
438
1.28
0.86
2.8
2.7
0.92
0.79
e6/l
0.17
36
214
8
45
1.80
0.85
1.6
1.7
13.20
13.30
%
—
8
45
25
181
1.41
0.83
1.4
1.4
—
—
—
0
0
21
147
1.46
0.82
2.8
3.3
142.24
132.31
g/l
1.24
21
142
81
695
1.22
0.80
2.4
2.3
—
—
—
0
0
6
33
1.83
0.79
1.0
1.2
—
—
—
0
0
6
33
1.83
0.79
1.0
1.2
—
—
—
0
0
6
33
1.83
0.79
1.0
1.2
—
—
—
0
0
80
689
1.21
0.76
2.3
2.1
2.62
2.65
mg/l
0.06
69
588
7
39
1.81
0.73
1.0
1.3
—
—
—
0
0
33
257
1.32
0.72
5.3
5.2
—
—
—
0
0
57
477
1.24
0.71
2.6
2.4
2.46
2.43
mmol/l
1.11
52
424
5
26
1.94
0.71
2.4
1.5
—
—
—
0
0
5
27
1.86
0.68
1.0
2.0
—
—
—
0
0
13
86
1.53
0.67
1.3
1.3
1.71
3.29
ug/l
1.68
13
79
5
28
1.80
0.66
1.8
3.9
12.80
73.73
u/ml
—
5
28
5
28
1.80
0.66
1.2
1.3
—
—
—
0
0
262
2522
1.21
0.63
3.9
3.7
1.32
1.22
mmol/l
1.35
247
2377
256
2460
1.20
0.62
5.8
5.3
37.60
38.00
mmol/mol
0.35
250
2350
63
542
1.20
0.61
1.3
1.3
7.53
10.45
u/ml
0.18
31
221
75
656
1.19
0.61
2.1
2.2
—
—
—
0
0
73
637
1.19
0.61
3.1
2.6
324.84
324.53
umol/l
0.01
67
580
40
328
1.25
0.61
4.2
3.1
5.35
7.41
umol/l
0.63
32
285
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
20
0.00
0.60
0.0
1.2
—
—
—
0
0
0
20
0.00
0.60
0.0
4.2
—
—
—
0
0
38
310
1.26
0.60
1.6
1.8
3.42
3.43
mmol/l
0.02
26
218
63
544
1.20
0.59
3.6
3.0
504.45
1019.86
ng/l
2.57
52
450
6
37
1.63
0.56
1.0
1.2
—
—
—
0
0
48
407
1.21
0.55
2.1
1.9
3.51
3.32
ratio
0.51
37
313
17
125
1.38
0.55
6.6
2.2
18.00
4.77
iu/ml
—
5
28
9
63
1.44
0.52
1.0
1.3
—
—
—
0
0
33
271
1.24
0.51
3.5
4.1
30.68
32.85
%
0.53
22
186
18
136
1.34
0.50
12.2
10.3
1.22
1.41
%
0.34
18
136
73
649
1.16
0.50
2.4
2.1
—
—
—
0
0
26
209
1.27
0.48
1.4
1.3
—
—
—
0
0
7
48
1.47
0.47
3.4
3.2
5.67
8.19
pmol/l
—
7
48
11
153
0.71
0.46
2.5
1.8
—
—
—
0
0
92
836
1.14
0.46
2.1
1.7
—
—
—
0
0
7
50
1.41
0.45
1.9
1.3
—
—
—
0
0
7
50
1.41
0.45
1.9
1.3
—
—
—
0
0
97
887
1.13
0.45
3.0
3.1
2.38
2.35
mmol/l
1.27
87
820
10
69
1.46
0.45
1.5
1.4
—
—
—
0
0
5
31
1.62
0.43
1.0
1.2
—
—
—
0
0
5
32
1.57
0.42
1.6
1.6
—
—
—
0
0
8
58
1.39
0.42
3.3
1.9
144.88
129.10
g/l
—
8
42
5
33
1.52
0.41
1.0
1.9
—
—
—
0
0
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
29
242
1.22
0.40
1.4
1.5
—
—
—
0
0
0
18
0.00
0.40
0.0
1.0
—
—
—
0
0
13
170
0.75
0.39
1.8
1.7
—
—
—
0
0
142
1344
1.10
0.35
2.6
2.7
—
—
estimate
—
0
0
13
166
0.77
0.34
15.3
8.4
24.91
24.85
mmol/l
0.03
13
166
26
221
1.19
0.31
2.9
2.4
9.68
14.23
au/ml
—
5
23
16
130
1.24
0.29
1.3
2.7
0.63
0.59
%
0.21
16
130
24
206
1.18
0.27
1.0
1.0
—
—
—
0
0
31
274
1.15
0.25
2.4
2.6
32.16
29.30
u/l
0.39
25
222
11
137
0.80
0.25
1.1
1.7
—
—
—
0
0
16
133
1.21
0.24
13.6
10.3
0.67
0.67
%
0.01
16
133
24
275
0.86
0.24
1.3
1.3
212.99
179.82
u/ml
—
10
117
6
85
0.70
0.24
1.2
3.3
22.83
853.30
u/ml
—
6
72
119
1138
1.07
0.22
1.8
1.9
1.28
1.33
mmol/l
0.35
108
1003
53
490
1.10
0.21
1.9
1.7
381.33
39019144.23
pmol/l
0.72
46
428
5
42
1.19
0.21
1.4
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
27.56
—
0
11
0
12
0.00
0.21
0.0
1.6
—
—
—
0
0
0
12
0.00
0.21
0.0
1.9
—
—
—
0
0
0
12
0.00
0.21
0.0
1.9
—
—
—
0
0
0
12
0.00
0.21
0.0
1.9
—
—
—
0
0
0
12
0.00
0.21
0.0
1.9
—
—
—
0
0
0
12
0.00
0.21
0.0
1.6
—
—
—
0
0
0
13
0.00
0.21
0.0
1.1
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
73
687
1.08
0.20
1.5
1.6
—
—
—
0
0
0
14
0.00
0.20
0.0
1.0
—
—
—
0
0
22
193
1.15
0.20
1.4
1.5
0.92
0.93
ratio
0.07
15
126
22
193
1.15
0.20
1.4
1.5
1.29
1.15
ratio
0.33
15
126
22
193
1.15
0.20
1.4
1.5
1.00
1.23
ratio
1.07
16
126
29
260
1.13
0.20
3.2
2.3
13031.99
7166.59
u/l
0.28
15
113
32
291
1.11
0.18
3.1
2.8
0.59
0.76
ug/l
0.82
17
164
73
693
1.07
0.16
1.7
1.6
19.89
21.13
nmol/l
0.37
65
595
8
71
1.13
0.16
1.0
1.4
3.50
3.67
mmol/l
—
8
65
8
73
1.10
0.16
1.1
1.3
—
—
—
0
0
25
226
1.12
0.15
2.8
3.0
—
—
—
0
0
9
78
1.16
0.15
1.2
1.3
—
66.42
—
0
9
9
79
1.14
0.15
1.3
2.1
9.94
10.19
g/l
—
9
74
11
129
0.85
0.15
1.6
1.6
65.35
50.30
ug/l
0.51
11
129
7
86
0.81
0.14
1.0
1.4
—
—
—
0
0
10
84
1.20
0.14
1.4
1.4
169.00
324.88
ug/g
—
5
42
50
472
1.07
0.13
4.4
4.6
1.38
1.82
ug/l
1.19
43
423
21
191
1.11
0.12
1.4
1.5
—
—
—
0
0
20
182
1.11
0.11
1.3
1.4
328.14
259.43
miu/ml
—
9
90
5
45
1.11
0.10
1.0
1.2
—
—
—
0
0
14
126
1.12
0.09
1.1
1.3
—
—
—
0
0
7
66
1.06
0.08
1.0
1.7
—
—
—
0
0
7
83
0.84
0.07
1.9
1.5
0.28
0.40
nmol/l
—
7
70
9
87
1.04
0.07
1.3
1.6
—
—
—
0
0
15
138
1.09
0.06
2.0
2.1
—
—
—
0
0
38
365
1.05
0.06
1.4
1.6
1203.68
928.78
mu/l
0.89
33
314
14
129
1.09
0.05
1.8
1.7
—
—
—
0
0
18
192
0.93
0.05
8.4
7.7
8.04
7.64
mmol/l
0.17
18
183
13
141
0.92
0.05
1.2
1.1
0.85
0.88
g/l
0.17
13
141
39
376
1.04
0.05
4.4
4.2
23.09
22.31
%
0.10
14
160
13
139
0.93
0.03
1.2
1.1
1.59
1.56
g/l
0.21
13
139
13
137
0.95
0.01
1.2
1.1
0.54
0.55
ratio
—
5
10
14
147
0.95
0.01
1.7
1.9
2.97
3.50
mg/l
—
9
103
19
183
1.04
0.01
3.5
2.5
75.57
75.25
ml/min/173m2
—
7
73
16
161
0.99
0.00
1.9
1.5
0.12
0.25
mg/l
—
8
70
13
134
0.97
0.00
1.4
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
1.21
—
0
6
0
9
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
0.01
—
0
5
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.1
—
44.84
—
0
7
5
51
0.98
-0.00
1.0
1.1
—
—
—
0
0
5
56
0.89
-0.00
1.8
4.2
3.56
3.88
mmol/l
—
5
56
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
9.13
—
0
5
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.4
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint L12_PITYROCHEA and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_PITYROCHEA | 1.391 [0.95, 2.03] | 0.087 |
| Birth year | 0.995 [0.99, 1.0] | 0.267 |
During the follow-up period (1.1.1998 — 31.12.2019), 58 out of 1019 females with L12_PITYROCHEA died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_PITYROCHEA | 1.467 [1.09, 1.98] | 0.013 |
| Birth year | 0.985 [0.97, 1.0] | 0.012 |
During the follow-up period (1.1.1998 — 31.12.2019), 67 out of 650 males with L12_PITYROCHEA died.
Mortality risk
Mortality risk for people of age
years, who have L12_PITYROCHEA.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.126% | 0.239% |
| 5 | 0.803% | 1.615% |
| 10 | 1.998% | 3.935% |
| 15 | 3.847% | 7.278% |
| 20 | 6.646% | 12.309% |
Relationships between endpoints
↥Index endpoint: L12_PITYROCHEA – Pityriasis rosea
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data